Vx-017

Phase 3

Vertex Pharmaceuticals

Vx-017 is one of 7 therapeutic programs targeting Diabetes Mellitus, Type 1. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diabetes Mellitus, Type 1Recruiting

Diabetes Mellitus, Type 1Phase 3

Recruiting

Competition

Competitive Landscape

7 competitors in Diabetes Mellitus, Type 1

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

1 2

Opzelura

Pfizer

Phase 2

1 3

Bacillus Calmette-Guérin

Bristol-Myers Squibb

Phase 2

1 4

Ozempic

Novo Nordisk

Phase 1

1 5

Vx-017

Vertex Pharmaceuticals

Phase 3

1 6

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 7

NNC0194-0499

Novo Nordisk

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 3Recruiting

Diabetes Mellitus, Type 1

NCT04786262

Clinical

Trials by Indication[1]

Diabetes Mellitus, Type 11 trial

A Master Protocol to Evaluate the Safety, Tolerability, and Efficacy of Islet Cell Replacement Therapies in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia: A Phase 1/2/3 Study of VX-880 and a Phase 1/2 Study of VX-017

Recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 3·NCT04786262·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vx-017. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Vx-017. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Vertex Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Vertex Pharmaceuticals

Vx-017

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Diabetes Mellitus, Type 11 trial

References

Drug Info

Quick Facts

Related News